COEP

$11.06

Pre-MarketAs of Mar 23, 8:00 PM UTC

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Recent News

MarketBeat
Jan 30, 2026

CSG Systems International Extraordinary General Meeting: Shareholders Back Key Proposals, Merger Actions

Coeptis Therapeutics Holdings Incorporated held its Annual and Special Meeting of Stockholders virtually, with Chief Executive Officer and Chairman Michael Mehalick presiding. The company noted the meeting was being recorded and outlined rules of conduct for participants using the webcast portal, in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.